News & Events about Verve Therapeutics Inc.
Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV Get Rating) by 58.4% during the 4th quarter, according to its most recent disclosure with the Securities Exchange Commission. The institutional investor owned 1,228,447 shares of the ...
Globe Newswire
3 months ago
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data to be Presented During an Oral Presentation at the2023 American College of Cardiologys Annual ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023...
Globe Newswire
5 months ago
NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. (Verve or the Company) (NASDAQ: VERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV PR Newswire NEW YORK, Dec. 26, 2022 NEW YORK, Dec. 26, 2022...